Investigational Drug Study of a New Formulation of Carbidopa/Levodopa for Early Stage Parkinson’s Disease

This is a clinical research study of a new formulation of carbidopa/levodopa, called IPX066, which is considered investigational since it has not been approved by the FDA. This study is for persons 30 years of age or older who have early stage Parkinson’s disease. The purpose of this research study is to find out whether IPX066 can effectively reduce the symptoms of Parkinson’s disease. There is no cost to participate in the study. If you are interested in learning more about the study, please call Boston University Parkinson’s Disease and Movement Disorder Center at 617-638-7736.

IRB H-28340